ArticleBritish journal of pharmacology2004
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 69 citations in OpenAlex.
- Subcritical Water Extraction ofMarine drugs · 2024Article
- Article
- CarrageenophyteMarine drugs · 2022Article
- Drug-Herb Interactions among Thai Herbs and Anticancer Drugs: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Inhibitory Effect of Tangeretin and Cardamonin on Human Intestinal SGLT1 Activity In Vitro and Blood Glucose Levels in Mice In Vivo.Nutrients · 2021Article
- Food dyes as P-glycoprotein modulators.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020Article
- Bitter Melon (Cancers · 2020Review
- Machine Learning Uncovers Food- and Excipient-Drug Interactions.Cell reports · 2020Article
- Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites.PloS one · 2020Article
- Article
- Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles.Pharmaceutics · 2018Review
- Article
- Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects.Frontiers in pharmacology · 2017Article
- Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.Seminars in cancer biology · 2016Review
- Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.Pharmaceuticals (Basel, Switzerland) · 2015Article
- Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance.Journal of pharmaceutical sciences · 2013Article
- Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells.Carcinogenesis · 2013Article
- A novel perspective and approach to intestinal octreotide absorption: sinomenine-mediated reversible tight junction opening and its molecular mechanism.International journal of molecular sciences · 2013Article
- Andrographis paniculata Extract and Andrographolide Modulate the Hepatic Drug Metabolism System and Plasma Tolbutamide Concentrations in Rats.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Advanced drug delivery reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracts of bitter melon, soybean, dokudami and welsh onion by 40% methanol increased the accumulation of rhodamine-123 by Caco-2 cells, suggesting that these extracts inhibited P-glycoprotein (P-gp). The extract of bitter melon was separated in a tC18 cartridge column and the eluate from 80% acetonitrile most markedly increased the [(3)H]-daunomycin accumulation by Caco-2 cells. The inhibitory compounds in the bitter melon fraction were isolated by HPLC with Pegasil C4 and Pegasil ODS columns. The HPLC fraction having the highest activity was analyzed by (1)H-NMR and FAB-MS, and the active compound was identified as 1-monopalmitin. The inhibitory activities of 1-monopalmitin and its related compounds suggested that the inhibition of P-gp activity was not dependent on the degree of unsaturation of fatty acid in the monoglyceride, but on the chain length. It was also suggested that the monoglyceride structure played an important role in the inhibition of P-gp activity. Monoglycerides could therefore alter the pharmacokinetics of drugs by inhibiting the P-gp-mediated efflux.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.